Biomarker

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Jason J Luke, Katherine Bever, F Stephen Hodi, Janis Taube, Ashish Massey, David Yao, Jaclyn Neely, Rachel Tam, George Lee, Akshita Gupta, Santanu Dutta, Peter Szabo, Riyue Bao, Tim Reilly

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011170; DOI: 10.1136/jitc-2024-011170
Tumor location as a risk factor for severe immune-related adverse events
Steven M Blum, Ben Ouyang, Leyre Zubiri, Daniel Leonard, Kamil Slowikowski, Mike Wang, Kelley A Grealish, Nora K Hathaway, Gabriel Molina, Nishi Shah, Donald P Lawrence, Michael Dougan, Alexandra-Chloe Villani, Mari Mino Kendusen, Kerry L Reynolds, Ryan J Sullivan

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011312; DOI: 10.1136/jitc-2024-011312
GP73: the key to unlocking immunotherapies efficacy in solid tumors?
Rebecca J Bayliss, Alan L Parker

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011989; DOI: 10.1136/jitc-2025-011989
FMO2⁺ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
Wenxin Xu, Jialei Weng, Yufei Zhao, Peiyi Xie, Minghao Xu, Shaoqing Liu, Qiang Yu, Mincheng Yu, Bugang Liang, Junbo Chen, Hui-Chuan Sun, Hui Li, Qinghai Ye, Yinghao Shen

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011648; DOI: 10.1136/jitc-2025-011648
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy
Andrew A. Almonte, Laurence Zitvogel

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011540; DOI: 10.1136/jitc-2025-011540
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer
Yilin Chen, Lu Yang, Yuhong Huang, Teng Zhu, Liulu Zhang, Minyi Cheng, Cangui Wu, Peiyong Li, Minting Liang, Xiaoqi Zhang, Hao Peng, Kun Wang

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e010365; DOI: 10.1136/jitc-2024-010365
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy
Nicole J Toney, Megan T Lynch, Filipa Lynce, Candace Mainor, Claudine Isaacs, Jeffrey Schlom, Renee N Donahue

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011379; DOI: 10.1136/jitc-2024-011379
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
Meiting Chen, Riqing Huang, Qixiang Rong, Wei Yang, Xiujiao Shen, Qi Sun, Ditian Shu, Kuikui Jiang, Cong Xue, Jing Peng, Xin An, Haifeng Li, Fei Xu, Yanxia Shi

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011314; DOI: 10.1136/jitc-2024-011314
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study
Pei Chen, Xuewei Wu, Shuixing Zhang

Journal for ImmunoTherapy of Cancer Mar 2025, 13 (3) e012007; DOI: 10.1136/jitc-2025-012007
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Thomas U Marron, Jason J Luke, Brianna Hoffner, Jane Perlmutter, Connie Szczepanek, Valsamo Anagnostou, Ann W Silk, Pedro J Romero, Elizabeth Garrett-Mayer, Leisha A Emens

Journal for ImmunoTherapy of Cancer Mar 2025, 13 (3) e010760; DOI: 10.1136/jitc-2024-010760

Main menu

Biomarker

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Biomarker

Pages